Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gilead Foundation

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

The companies will focus on advancing Kymera’s oral molecular glue degrader programme

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

FREE WEBINAR – Not Just a Number: Making Sure Every Voice Shapes the Future of Medicine – Origins & ISPEP

What Does Patient-focused Healthcare Really Mean? Healthcare is built around patients, but too often, their voices are an afterthought. Truly patient-focused medicine isn’t just about treatment - it’s about understanding...

Origins – The Patient Focused Specialists

- PMLiVE

REGISTER NOW – Not Just a Number: Making Sure Every Voice Shapes the Future of Medicine

Health Equity: Why Lived Experience Matters Medicine is constantly evolving, but progress is only meaningful if it reaches everyone. Health outcomes are shaped not just by science, but by social...

Origins – The Patient Focused Specialists

- PMLiVE

Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

Primary biliary cholangitis affects approximately 163,000 people in Europe

- PMLiVE

Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

The company gained access to the drug through its $4.3bn acquisition of CymaBay

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

Gilead appoints Dietmar Berger as chief medical officer

Berger most recently served as chief medical officer and global head of development at Sanofi

- PMLiVE

Gilead and AI-focused Genesis partner to develop small molecule therapies

The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

- PMLiVE

Hear From Her: Extraordinary Women Who Are Redefining Healthcare Leadership

That’s a wrap for Season 2 of Medscape Education’s Award-Winning Podcast Series, Hear From Her: Women in Healthcare Leadership! (Not to worry, Season 3 is just around the corner.)  And...

Medscape Education

- PMLiVE

Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links